June 04, 2010 02:19am EST 

Sudden Cardiac Arrest is the leading cause of death in the United States, accounting for approximately 325,000 deaths every year. Those who suffer from Sudden Cardiac Arrest (SCA) are at high risk of death, especially if medical attention is not immediately administered. Fortunately, there is the AutoPulse Non-Invasive Cardiac Support Pump, made by ZOLL Medical Corporation.
This device, the only one of its kind, provides those suffering from SCA with a much more stable and consistent chest compressions — allowing more blood flow to both the heart and the brain. This is essential for the survival of SCA victims, as it allows rescuers to perform other life-saving activities while the device provides constant, high-quality compressions to improve blood flow. The improved blood flow allows hospital workers better access resulting in a shown triple survival rate until hospital discharge. There is no question that the device helps improve the chance of survival following a SCA. What makes the device even more impressive is its ability to adjust automatically to each patient’s unique chest, as well as its intuitive easy-to-use nature.
ZOLL Medical Corporation, the creator of the AutoPulse Pump, is a corporation leading the charge in medical products and software solutions that help emergency responders save lives in emergency situations occurring in any place imaginable. They are committed to improve resuscitation outcomes through their many products, effectively increasing the efficiency of emergency operations.
The corporation has had its share of impressive professional milestones, including making the Forbes Top 100 Most Trustworthy Companies list for all three of its publications — only one of ten companies able to boast such an accomplishment. Additionally, ZOLL’s products are being used all throughout the world, by the thousands, and continually win awards and recognitions for their efficacy and affordability. Their LifeVest, promoted as the world’s first and only wearable defibrillator, has 17,596 patients as of September 1, 2009. Each of their products are aimed to deliver superior clinical performance, rapid therapy, meaningful information, higher user confidence, and economic value.